Jason Carroll (researcher)

Professor Jason Carroll FMedSci is a British medical researcher serving as a Senior Group Leader at the Cambridge Biomedical Campus, University of Cambridge and Founder and Chief Scientific Officer of Azeria Therapeutics.[1][2] He is a Professor of Molecular Oncology assigned to the Department of Oncology[3] and a Fellow of Clare College, Cambridge.[4]

Jason Carroll

FMedSci
Alma materUniversity of Melbourne
AwardsFellow of the Academy of Medical Sciences
Scientific career
InstitutionsCancer Research UK Cambridge Institute, University of Cambridge
Websitewww.cruk.cam.ac.uk/research-groups/carroll-group

Education

Carroll completed his B.Sc Hons in Molecular Biology at the University of Melbourne before undertaking his PhD in Cancer Research at The Garvan Institute and University of New South Wales.[2]

Career

Carroll's research uses molecular, genomic and proteomic approaches to understand how the Estrogen Receptor causes gene transcription and how this contributes to breast cancer progression.[5] In 2008, Carroll discovered the molecular mechanism of tamoxifen in breast cancer, demonstrating that tamoxifen switched off the breast cancer gene ErbB2 via the protein Pax2, which acts as a switch. The team showed that tamoxifen resistance occurs when ErbB2 remains on.[6][7][8] Carroll also discovered the role of pioneer factor FOXA1 in breast cancer, demonstrating that it is key in enabling the estrogen receptor to interact with the DNA in breast cancer cells, switching on genes that trigger unchecked growth.[9][10] In 2015, Carroll's work uncovered why women who have high levels of both the estrogen and progesterone receptors have a better chance of breast cancer survival, and found that adding progesterone at the same time as tamoxifen slows tumour growth in the laboratory.[11][12][13]

In 2017, Carroll founded Azeria Therapeutics Limited to develop treatments for hormone resistant breast and prostate cancer, building on his work with pioneer factor FOXA1.[2][14][15]

Awards and Honours

References
  1. "Carroll Group". Cancer Research UK Cambridge Institute. Retrieved 2019-09-03.
  2. "Azeria Therapeutics | Developing pioneering cancer treatments". Azeria Therapeutics. Retrieved 2019-09-03.
  3. "Institute Group Leaders awarded promotions in the University". Cancer Research UK Cambridge Institute. 2019-07-24. Retrieved 2019-09-03.
  4. "Fellows of Clare College - Clare College Cambridge". www.clare.cam.ac.uk. Retrieved 2019-09-03.
  5. "Jason Carroll - Google Scholar Citations". scholar.google.com. Retrieved 2019-09-03.
  6. Carroll, Jason S.; Ali, Simak; Howat, William J.; Jiang, Jie; Myles Brown; Nicholson, Robert I.; Hutcheson, Iain R.; Geistlinger, Timothy R.; Holmes, Kelly A. (December 2008). "Regulation of ERBB2 by oestrogen receptor–PAX2 determines response to tamoxifen". Nature. 456 (7222): 663–666. doi:10.1038/nature07483. ISSN 1476-4687. PMC 2920208. PMID 19005469.
  7. "Breast drug failure cause found". 2008-11-13. Retrieved 2019-09-03.
  8. "Scientists crack the code to tamoxifen resistance". University of Cambridge. 2008-11-13. Retrieved 2019-09-03.
  9. Carroll, Jason S.; Schmidt, Dominic; Ross-Innes, Caryn S.; Holmes, Kelly A.; Hurtado, Antoni (January 2011). "FOXA1 is a key determinant of estrogen receptor function and endocrine response". Nature Genetics. 43 (1): 27–33. doi:10.1038/ng.730. ISSN 1546-1718. PMC 3024537. PMID 21151129.
  10. "Single gene essential for oestrogen response in breast cancer". Cancer Research UK. 2013-12-05. Retrieved 2019-09-03.
  11. editor, Ian Sample Science (2015-07-08). "Breast cancer hope as hormone shown to slow tumour growth". The Guardian. ISSN 0261-3077. Retrieved 2019-09-03.CS1 maint: extra text: authors list (link)
  12. "Solving a breast cancer mystery – why do 'double-positive' women do better?". Cancer Research UK - Science blog. Retrieved 2019-09-03.
  13. Carroll, Jason S.; Tilley, Wayne D.; Caldas, Carlos; Stingl, John; Perou, Charles M.; Launchbury, Rosalind; Silva, Grace; Robinson, Jessica L. L.; D’Santos, Clive (July 2015). "Progesterone receptor modulates ERα action in breast cancer". Nature. 523 (7560): 313–317. doi:10.1038/nature14583. ISSN 1476-4687. PMC 4650274. PMID 26153859.
  14. "Azeria Therapeutics | Business Weekly | Technology News | Business news | Cambridge and the East of England". www.businessweekly.co.uk. Retrieved 2019-09-03.
  15. Therapeutics, Azeria. "Azeria Therapeutics, the World's First Pioneer Factor Drug Discovery Company, Announces Series A Investment from Sixth Element Capital". www.prnewswire.co.uk. Retrieved 2019-09-03.
  16. "BACR/AstraZeneca Young Scientist Frank Rose Award | BACR - The British Association for Cancer Research". www.bacr.org.uk. Retrieved 2019-09-03.
  17. adit. "Twenty-one group leaders join network of EMBO Young Investigators". EMBO. Retrieved 2019-09-03.
  18. "Future Leaders in Cancer Research Prize". Cancer Research UK. 2015-10-28. Retrieved 2019-09-03.
  19. "Jason Carroll receives AACR Outstanding Investigator Award Scholarship". Cancer Research UK Cambridge Institute. 2013-09-26. Retrieved 2019-09-03.
  20. "AACR Outstanding Investigator Award for Breast Cancer Research, supported by The Breast Cancer Research Foundation". www.aacr.org. Retrieved 2019-09-03.
  21. admin (2017-09-17). "Louis-Jeantet Young Investigator Career Award | Jeantet". Retrieved 2019-09-03.
  22. "Find people in the EMBO Communities". people.embo.org. Retrieved 2019-09-03.
  23. "The Academy of Medical Sciences announces new Fellows for 2017". University of Cambridge. 2017-05-08. Retrieved 2019-09-03.
  24. "Dr Jason Carroll | The Academy of Medical Sciences". acmedsci.ac.uk. Retrieved 2019-09-03.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.